BACKGROUND: We introduced domiciliary intravenous (IV) antibiotic therapy in @entity1 with @entity4595 to promote @entity1 -centred domiciliary treatment instead of hospital inpatient treatment. AIM: To assess the efficacy and safety of domiciliary IV antibiotic therapy in @entity1 with non-cystic @entity82 @entity4595 . METHODS: In this prospective study conducted over 5 years, we assessed @entity1 ' eligibility for receiving domiciliary treatment. All @entity1 received 14 days of IV antibiotic therapy and were monitored at baseline/day 7/day 14. We assessed the treatment outcome, morbidity, mortality and 30-day readmission rates. RESULTS: A total of 116 @entity1 received 196 courses of IV antibiotics. Eighty courses were delivered as inpatient treatment, 32 as early supported discharge (ESD) and 84 as domiciliary therapy. There was significant clinical and quality of life improvement in all groups, with resolution of @entity281 in 76% in the inpatient group, 80% in the ESD group and 80% in the domiciliary group. Morbidity was recorded in 13.8% in the inpatient group, 9.4% in the ESD group and 14.2% in the domiciliary IV group. No mortality was recorded in either group. Thirty-day readmission rates were 13.8% in the inpatient group, 12.5% in the ESD group and 14.2% in the domiciliary group. Total bed days saved was 1443. CONCLUSION: Domiciliary IV antibiotic therapy in @entity4595 is clinically effective and was safe in our cohort of @entity1 .

A prospective cohort study of the use of domiciliary intravenous antibiotics in XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infection'] @entity82 :: ('MESH:D005355', 'Disease') :: ['fibrosis'] @entity4595 :: ('MESH:D001987', 'Disease') :: ['bronchiectasis']
@entity4595 :: (MESH:D001987,Disease) :: ['bronchiectasis']
